Luminary Therapeutics is a clinical-stage allogeneic cell therapy company focused on combining advanced receptor design with superior cell engineering to overcome antigen escape and T cell dysfunction. Luminary was founded by the team from B-MoGen, which was acquired by Bio-Techne in 2019.
Investors 1
| Date | Name | Website |
| - | Myeloma In... | myelomainv... |
Mentions in press and media 2
| Date | Title | Description |
| 07.12.2022 | Dr. Joseph Eid to join Luminary Therapeutics as Chief Medical Officer | Dr. Eid Luminary announces a new Chief Medical Officer MINNEAPOLIS, MN, UNITED STATES, December 7, 2022 /EINPresswire.com/ -- Luminary is announcing the appointment of Dr. Joseph Eid as the organization's new fractional Chief Medical Office... |
| 19.07.2022 | Luminary Therapeutics selected as a 2022/2023 Showcase Company in NIH/NCI’s investor initiative program | Luminary Therapeutics a clinical stage gamma delta allogeneic cellular therapy company. MINNEAPOLIS, MN, USA, July 19, 2022 /EINPresswire.com/ -- Luminary Therapeutics was selected as a 2022/2023 Showcase Company in NIH/NCI’s investor initi... |